The coronavirus disease (COVID-19) caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has now spread to >200 countries posing a global public health concern. Patients with comorbidity, such as hypertension suffer more severe infection with elevated mortality. The development of effective antiviral drugs is in urgent need to treat COVID-19 patients. Here, we report that calcium channel blockers (CCBs), a type of antihypertensive drug that is widely used in clinics, inhibited the post-entry replication events of SARS-CoV-2 in vitro, while no in vitro anti-SARS-CoV-2 effect was observed for the two other major types of antihypertensive drugs, namely, angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers. CCB combined with chloroquine showed a significantly enhanced anti-SARS-CoV-2 efficacy. A retrospective clinical investigation on hospitalized COVID-19 patients with hypertension as the only comorbidity revealed that the CCB amlodipine besylate therapy was associated with a decreased case fatality rate. The results from this study suggest that CCB administration to COVID-19 patients with hypertension as the comorbidity might improve the disease outcome.
基金：
National Science and Technology Major Project [2018ZX10101004001005]; Natural Science Foundation of China [31970165, 81825019, 81722041, 31770188]; Open Research Fund Program of Wuhan National Bio-Safety Level 4 Lab of CAS [2018ACCP-MS01, 2020ACCP-MS02]; Hubei Science and Technology Project [2020FCA003]; Youth Innovation Promotion Association CAS [2018367]
第一作者单位：[1]Chinese Acad Sci, Wuhan Inst Virol, Ctr Biosafety Mega Sci, State Key Lab Virol, Wuhan 430071, Hubei, Peoples R China
通讯作者：
推荐引用方式(GB/T 7714)：
Zhang Lei-Ke,Sun Yuan,Zeng Haolong,et al.Calcium channel blocker amlodipine besylate therapy is associated with reduced case fatality rate of COVID-19 patients with hypertension[J].CELL DISCOVERY.2020,6(1):doi:10.1038/s41421-020-00235-0.
APA：
Zhang, Lei-Ke,Sun, Yuan,Zeng, Haolong,Wang, Qingxing,Jiang, Xiaming...&Xiao, Gengfu.(2020).Calcium channel blocker amlodipine besylate therapy is associated with reduced case fatality rate of COVID-19 patients with hypertension.CELL DISCOVERY,6,(1)
MLA：
Zhang, Lei-Ke,et al."Calcium channel blocker amlodipine besylate therapy is associated with reduced case fatality rate of COVID-19 patients with hypertension".CELL DISCOVERY 6..1(2020)
生物学